Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission,...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Blood Ročník 130; číslo 25; s. 2709
Hlavní autoři:	Pro, Barbara, Advani, Ranjana, Brice, Pauline, Bartlett, Nancy L, Rosenblatt, Joseph D, Illidge, Tim, Matous, Jeffrey, Ramchandren, Radhakrishnan, Fanale, Michelle, Connors, Joseph M, Fenton, Keenan, Huebner, Dirk, Pinelli, Juan M, Kennedy, Dana A, Shustov, Andrei
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 21.12.2017
Témata:	Adolescent Adult Aged Brentuximab Vedotin Disease Progression Disease-Free Survival Female Humans Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Longitudinal Studies Lymphoma, Large-Cell, Anaplastic - complications Lymphoma, Large-Cell, Anaplastic - drug therapy Lymphoma, Large-Cell, Anaplastic - pathology Male Middle Aged Peripheral Nervous System Diseases - etiology Remission Induction Salvage Therapy - methods Stem Cell Transplantation Survival Analysis Treatment Outcome Young Adult
ISSN:	1528-0020, 1528-0020
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!